RESEARCH TRIANGLE PARK, N.C.—Biopharmaceutical company Tranzyme Pharma announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its application entitled "Combinatorial Synthesis of Libraries of Macrocyclic Compounds". The patent covers aspects of its proprietary drug design and medicinal chemistry platform, Macrocyclic Template Chemistry (MATCH), which it has used to develop small-molecule compounds targeting gastrointestinal and metabolic disorders.
"We are very excited with the significant progress that we have made in demonstrating the ability of our chemistry to produce a pipeline of high-quality drug candidates for internal development," says Dr. Vipin K. Garg, company president and CEO. "Our strategy is to further leverage this technology in joint drug discovery and development alliances across multiple therapeutic areas."
MATCH allows Tranzyme to develop small-molecule drug candidates that mimic the specificity and potency of protein-peptide interactions while eliminating the more negative impacts of metabolic instability, low oral bioavailability and antigenicity.
